These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 18676143)
21. Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors. Cirillo PF; Hickey ER; Moss N; Breitfelder S; Betageri R; Fadra T; Gaenzler F; Gilmore T; Goldberg DR; Kamhi V; Kirrane T; Kroe RR; Madwed J; Moriak M; Netherton M; Pargellis CA; Patel UR; Qian KC; Sharma R; Sun S; Swinamer A; Torcellini C; Takahashi H; Tsang M; Xiong Z Bioorg Med Chem Lett; 2009 May; 19(9):2386-91. PubMed ID: 19356929 [TBL] [Abstract][Full Text] [Related]
22. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571 [TBL] [Abstract][Full Text] [Related]
23. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds. Caballero J; Alzate-Morales JH; Vergara-Jaque A J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048 [TBL] [Abstract][Full Text] [Related]
26. Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors. Gopalsamy A; Ciszewski G; Shi M; Berger D; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R Bioorg Med Chem Lett; 2009 Dec; 19(24):6890-2. PubMed ID: 19884006 [TBL] [Abstract][Full Text] [Related]
27. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850 [TBL] [Abstract][Full Text] [Related]
28. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase. Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962 [TBL] [Abstract][Full Text] [Related]
29. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors. Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453 [TBL] [Abstract][Full Text] [Related]
30. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site. Alzate-Morales JH; Vergara-Jaque A; Caballero J J Chem Inf Model; 2010 Jun; 50(6):1101-12. PubMed ID: 20524689 [TBL] [Abstract][Full Text] [Related]
31. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors. Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972 [TBL] [Abstract][Full Text] [Related]
32. Stabilization of a closed kinase conformation induces RAF dimerization. Cancer Discov; 2013 Jul; 3(7):715. PubMed ID: 23847340 [TBL] [Abstract][Full Text] [Related]
33. 5-amino-pyrazoles as potent and selective p38α inhibitors. Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336 [TBL] [Abstract][Full Text] [Related]
34. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462 [TBL] [Abstract][Full Text] [Related]